Merck, Ablynx ink immunotherapy deal

Merck and Belgium's Ablynx have signed their second collaboration and licensing deal. Ablynx announced the $27-million partnership Monday. The agreement focuses on nanobodies that can be deployed for immuno-oncology treatments. The three-year research agreement also promises up to $14.5 million in research funding and royalties that could reach $2.3 billion.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.